Filing Flows › Thermo Fisher Scientific (TMO) › Q3 2026 › vs Q2 2026
Thermo Fisher Scientific (TMO) Q3 2026 vs Q2 2026 (quarter over quarter)
Thermo Fisher Scientific's revenue rose $143M (+1%) from $12.0B in Q2 2026 to $12.1B in Q3 2026. The biggest changes: Laboratory Products and Biopharma Services +$168M (+3%); Analytical Instruments +$149M (+8%); Specialty Diagnostics −$98.0M (-8%). Operating margin 18.6% against 17.4% (+1.2 pts).
Thermo Fisher Scientific, Q3 2026: revenue $12.1B (+9% year over year), operating margin 18.6%, net earnings $1.7B, operating cash flow $2.5B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 18.6% | 17.4% | +1.2 pts |
| Net margin | 14.2% | 14.5% | -0.3 pts |
| Free cash flow margin | 17.4% | 14.0% | +3.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Laboratory Products and Biopharma Services | $6.8B | $6.7B | $168M | +3% |
| Life Sciences Solutions | $2.3B | $2.4B | −$76.0M | -3% |
| Analytical Instruments | $1.9B | $1.8B | $149M | +8% |
| Specialty Diagnostics | $1.1B | $1.2B | −$98.0M | -8% |
| Revenue | $12.1B | $12.0B | $143M | +1% |
| Operating profit | $2.3B | $2.1B | $176M | +8% |
| Costs & expenses | $9.9B | $9.9B | −$33.0M | -0.3% |
| Pre-tax earnings | $2.1B | $1.9B | $171M | +9% |
| Other expense, net | $184M | $179M | $5.0M | +3% |
| Research & development | $348M | $364M | −$16.0M | -4% |
| SG&A | $2.3B | $2.3B | −$12.0M | -0.5% |
| Other operating costs | $7.2B | $7.2B | −$5.0M | -0.1% |
| Net earnings | $1.7B | $1.7B | −$14.0M | -0.8% |
| Income tax | $352M | $167M | $185M | +111% |
| Depreciation & amortization | $825M | $816M | $9.0M | +1% |
| Share-based compensation | $96.0M | $82.0M | $14.0M | +17% |
| Working capital & other | $98.0M | $514M | −$416M | -81% |
| Operating cash flow | $2.5B | $2.1B | $425M | +20% |
| Free cash flow (OCF − capex) | $2.1B | $1.7B | $438M | +26% |
| Capital expenditures | $437M | $450M | −$13.0M | -3% |
Questions
How much did Thermo Fisher Scientific's revenue grow quarter over quarter in Q3 2026?
Thermo Fisher Scientific's revenue rose $143M (+1%) from $12.0B in Q2 2026 to $12.1B in Q3 2026.
What drove Thermo Fisher Scientific's revenue change in Q3 2026?
Laboratory Products and Biopharma Services +$168M (+3%); Analytical Instruments +$149M (+8%); Specialty Diagnostics −$98.0M (-8%).